18 results on '"Paoloni, Maurizio"'
Search Results
2. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units
- Author
-
Carubbi, Francesco, Salvati, Lia, Alunno, Alessia, Maggi, Fabio, Borghi, Erika, Mariani, Rinalda, Mai, Francesca, Paoloni, Maurizio, Ferri, Claudio, Desideri, Giovambattista, Cicogna, Sabrina, and Grassi, Davide
- Published
- 2021
- Full Text
- View/download PDF
3. High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening
- Author
-
Polilli, Ennio, Tontodonati, Monica, Flacco, Maria Elena, Ursini, Tamara, Striani, Palmira, Di Giammartino, Dante, Paoloni, Maurizio, Vallarola, Luigi, Pressanti, Gabriella Lucidi, Fragassi, Giorgia, Accorsi, Patrizia, Manzoli, Lamberto, and Parruti, Giustino
- Published
- 2016
- Full Text
- View/download PDF
4. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression
- Author
-
Salpini, Romina, Colagrossi, Luna, Bellocchi, Maria Concetta, Surdo, Matteo, Becker, Christina, Alteri, Claudia, Aragri, Marianna, Ricciardi, Alessandra, Armenia, Daniele, Pollicita, Michela, Di Santo, Fabiola, Carioti, Luca, Louzoun, Yoram, Mastroianni, Claudio Maria, Lichtner, Miriam, Paoloni, Maurizio, Esposito, Mariarosaria, DʼAmore, Chiara, Marrone, Aldo, Marignani, Massimo, Sarrecchia, Cesare, Sarmati, Loredana, Andreoni, Massimo, Angelico, Mario, Verheyen, Jens, Perno, Carlo-Federico, and Svicher, Valentina
- Published
- 2015
- Full Text
- View/download PDF
5. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 Units.
- Author
-
Carubbi, Francesco, primary, Salvati, Lia, additional, Alunno, Alessia, additional, Maggi, Fabio, additional, Borghi, Erika, additional, Mariani, Rinalda, additional, Mai, Francesca, additional, Paoloni, Maurizio, additional, Ferri, Claudio, additional, Desideri, Giovambattista, additional, Cicogna, Sabrina, additional, and Grassi, Davide, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
- Author
-
Salpini, Romina, primary, Battisti, Arianna, additional, Piermatteo, Lorenzo, additional, Carioti, Luca, additional, Anastasiou, Olympia E., additional, Gill, Upkar S., additional, Di Carlo, Domenico, additional, Colagrossi, Luna, additional, Duca, Leonardo, additional, Bertoli, Ada, additional, La Rosa, Katia Yu, additional, Fabeni, Lavinia, additional, Iuvara, Alessandra, additional, Malagnino, Vincenzo, additional, Cerva, Carlotta, additional, Lichtner, Miriam, additional, Mastroianni, Claudio M., additional, De Sanctis, Giuseppe Maria, additional, Paoloni, Maurizio, additional, Marignani, Massimo, additional, Pasquazzi, Caterina, additional, Iapadre, Nerio, additional, Parruti, Giustino, additional, Vecchiet, Jacopo, additional, Sarmati, Loredana, additional, Andreoni, Massimo, additional, Angelico, Mario, additional, Grelli, Sandro, additional, T. Kennedy, Patrick, additional, Verheyen, Jens, additional, Aquaro, Stefano, additional, Ceccherini-Silberstein, Francesca, additional, Perno, Carlo Federico, additional, and Svicher, Valentina, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy
- Author
-
Bertoli, Ada, Sorbo, Maria Chiara, Aragri, Marianna, Lenci, Ilaria, Teti, Elisabetta, Polilli, Ennio, Di Maio, Velia Chiara, Gianserra, Laura, Biliotti, Elisa, Masetti, Chiara, Magni, Carlo F., Babudieri, Sergio, Nicolini, Laura A., Milana, Martina, Cacciatore, Pierluigi, Sarmati, Loredana, Pellicelli, Adriano, Paolucci, Stefania, Craxì, Antonio, Morisco, Filomena, Palitti, Valeria Pace, Siciliano, Massimo, Coppola, Nicola, Iapadre, Nerio, Puoti, Massimo, Rizzardini, Giuliano, Taliani, Gloria, Pasquazzi, Caterina, Andreoni, Massimo, Parruti, Giustino, Angelico, Mario, Perno, Carlo Federico, Cento, Valeria, Ceccherini-Silberstein, Francesca, Andreone, Pietro, Baldanti, Fausto, Barbarini, Giorgio, Boccaccio, Vincenzo, Boglione, Lucio, Bolis, Matteo, Bonora, Stefano, Borghi, Vanni, Brancaccio, Giuseppina, Bruno, Savino, Bruzzone, Bianca, Calvaruso, Vincenza, Caporaso, Nicola, Ciaccio, Antonio, Ciancio, Alessia, Colombatto, Piero, Cozzolongo, Raffaele, D'Ambrosio, Cecilia, D'Ettorre, Gabriella, De Leonardis, Francesco, De Luca, Andrea, Di Biagio, Antonio, Di Perri, Giovanni, Francioso, Simona, Gaeta, Giovanni Battista, Gasbarrini, Antonio, Ghisetti, Valeria, Giorgini, Alessia, Grieco, Antonio, Gubertini, Guido, Gulminetti, Roberto, Lambiase, Lara, Landonio, Simona, Lichtner, Miriam, Maida, Ivana, Marenco, Simona, Marinaro, Letizia, Maserati, Renato, Melis, Michela, Menzaghi, Barbara, Meregalli, Elisa, Micheli, Valeria, Niero, Fosca, Paoloni, Maurizio, Pieri, Alessandro, Rendina, Maria, Romagnoli, Dante, Rossetti, Barbara, Ruggiero, Tina, Sangiovanni, Vincenzo, Starace, Mario, Sticchi, Laura, Tarquini, Pierluigi, Toniutto, Pierluigi, Vullo, Vincenzo, Zazzi, Maurizio, HCV Virology Italian Resistance Network, Bertoli A1, Sorbo MC1, Aragri M1, Lenci I2, Teti E3, Polilli E4, Di Maio VC1, Gianserra L5, Biliotti E6, Masetti C2, Magni CF7, Babudieri S8, Nicolini LA9, Milana M2, Cacciatore P4, Sarmati L3, Pellicelli A10, Paolucci S11, Craxì A, Morisco F13, Palitti VP14, Siciliano M15, Coppola N16, Iapadre N17, Puoti M18, Rizzardini G7, Taliani G6, Pasquazzi C5, Andreoni M3, Parruti G4, Angelico M2, Perno CF19, Cento V20, Ceccherini-Silberstein F1, HCV Virology Italian Resistance Network (VIRONET-C)., Bertoli, Ada, Sorbo, Maria Chiara, Aragri, Marianna, Lenci, Ilaria, Teti, Elisabetta, Polilli, Ennio, Di Maio, Velia Chiara, Gianserra, Laura, Biliotti, Elisa, Masetti, Chiara, Magni, Carlo F., Babudieri, Sergio, Nicolini, Laura A., Milana, Martina, Cacciatore, Pierluigi, Sarmati, Loredana, Pellicelli, Adriano, Paolucci, Stefania, Craxì, Antonio, Morisco, Filomena, Palitti, Valeria Pace, Siciliano, Massimo, Coppola, Nicola, Iapadre, Nerio, Puoti, Massimo, Rizzardini, Giuliano, Taliani, Gloria, Pasquazzi, Caterina, Andreoni, Massimo, Parruti, Giustino, Angelico, Mario, Perno, Carlo Federico, Cento, Valeria, Ceccherini-Silberstein, Francesca, Andreone, Pietro, Baldanti, Fausto, Barbarini, Giorgio, Boccaccio, Vincenzo, Boglione, Lucio, Bolis, Matteo, Bonora, Stefano, Borghi, Vanni, Brancaccio, Giuseppina, Bruno, Savino, Bruzzone, Bianca, Calvaruso, Vincenza, Caporaso, Nicola, Ciaccio, Antonio, Ciancio, Alessia, Colombatto, Piero, Cozzolongo, Raffaele, D'Ambrosio, Cecilia, D'Ettorre, Gabriella, De Leonardis, Francesco, De Luca, Andrea, Di Biagio, Antonio, Di Perri, Giovanni, Francioso, Simona, Gaeta, Giovanni Battista, Gasbarrini, Antonio, Ghisetti, Valeria, Giorgini, Alessia, Grieco, Antonio, Gubertini, Guido, Gulminetti, Roberto, Lambiase, Lara, Landonio, Simona, Lichtner, Miriam, Maida, Ivana, Marenco, Simona, Marinaro, Letizia, Maserati, Renato, Melis, Michela, Menzaghi, Barbara, Meregalli, Elisa, Micheli, Valeria, Niero, Fosca, Paoloni, Maurizio, Pieri, Alessandro, Rendina, Maria, Romagnoli, Dante, Rossetti, Barbara, Ruggiero, Tina, Sangiovanni, Vincenzo, Starace, Mario, Sticchi, Laura, Tarquini, Pierluigi, Toniutto, Pierluigi, Vullo, Vincenzo, Zazzi, Maurizio, Bertoli, A, Sorbo, M, Aragri, M, Lenci, I, Teti, E, Polilli, E, Di Maio, V, Gianserra, L, Biliotti, E, Masetti, C, Magni, C, Babudieri, S, Nicolini, L, Milana, M, Cacciatore, P, Sarmati, L, Pellicelli, A, Paolucci, S, Craxi, A, Morisco, F, Palitti, V, Siciliano, M, Coppola, N, Iapadre, N, Puoti, M, Rizzardini, G, Taliani, G, Pasquazzi, C, Andreoni, M, Parruti, G, Angelico, M, Perno, C, Cento, V, Ceccherini-Silberstein, F, Andreone, P, Baldanti, F, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Bruzzone, B, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, D'Ambrosio, C, D'Ettorre, G, De Leonardis, F, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Gasbarrini, A, Ghisetti, V, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Landonio, S, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Melis, M, Menzaghi, B, Meregalli, E, Micheli, V, Niero, F, Paoloni, M, Pieri, A, Rendina, M, Romagnoli, D, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Zazzi, M, Sorbo, Mc, Di Maio, Vc, Magni, Cf, Nicolini, La, Craxì, A, Palitti, Vp, Perno, Cf, Gaeta, Gb, and Zazzi, M.
- Subjects
Male ,0301 basic medicine ,Sofosbuvir ,Hepacivirus ,Drug Resistance ,lcsh:Medicine ,Viral Nonstructural Proteins ,medicine.disease_cause ,Gastroenterology ,Hepatitis C Virus ,HCV resistance-test ,chemistry.chemical_compound ,0302 clinical medicine ,Genotype ,Prevalence ,Viral ,lcsh:Science ,Multidisciplinary ,biology ,Hepatitis C ,Middle Aged ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Italy ,Cohort ,HCV ,Female ,030211 gastroenterology & hepatology ,medicine.drug ,Adult ,medicine.medical_specialty ,HCV RAS ,Hepatitis C virus ,03 medical and health sciences ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,Aged ,NS5A ,NS5B ,business.industry ,lcsh:R ,Hepatitis C Virus, HCV resistance-test ,biology.organism_classification ,medicine.disease ,030104 developmental biology ,chemistry ,lcsh:Q ,business - Abstract
Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mainly due to 80K presence in GT1a (17%). Almost all GTs showed high prevalence of NS5A-RASs (range: 10.2–45.4%), and especially of 93H (5.1%). NS5A-RASs with fold-change >100x were detected in 6.8% GT1a (30H/R-31M-93C/H), 10.3% GT1b (31V-93H), 28.4% GT2c (28C-31M-93H), 8.5% GT3a (30K-93H), 45.5% GT4a (28M-30R-93H) and 3.8% GT4d (28V-30S-93H). Sofosbuvir RAS 282T was never detected, while the 159F and 316N RASs were found in GT1b (13.4–19.1%, respectively). Natural RASs are common in Italian patients infected with HCV-GTs 1–4. High prevalence of clinically-relevant RASs (such as Y93H) supports the appropriateness of HCV resistance-test to properly guide DAA-based therapy.
- Published
- 2018
8. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
- Author
-
Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio Maria, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F., Ceccherini Silberstein, Francesca, Mariani, R., Iapadre, N., Grimaldi, A., Cozzolongo, R., Andreone, P., Verucchi, G., Menzaghi, B., Quirino, T., Pisani, V., Torti, MARIA CHIARA, Vecchiet, J., Bruzzone, B., De Maria, A., Marenco, S., Nicolini, L. A., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, Miriam, Aghemo, A., Boccaccio, V., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Lleo, A., Magni, C. F., Mancon, A., Monico, S., Niero, F., Russo, M. L., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Brancaccio, G., Gaeta, G. B., Lembo, V., Sangiovanni, V., Di Marco, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pieri, A., Polilli, E., Sozio, F., Antenucci, F., Aragri, M., Baiocchi, L., Barbaliscia, S., Biliotti, Elisa, Biolato, M., Carioti, L., Ceccherini Silberstein, F., Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettorre, G., De Leonardis, F., De Sanctis, A., Di Maio, V. C., Di Paolo, D., Furlan, Caterina, Gallo, P., Gasbarrini, A., Giannelli, V., Grieco, S., Lambiase, L., Lattanzi, B., Lenci, I., Lula, R., Malagnino, V., Manuelli, M., Miglioresi, L., Milana, M., Moretti, A., Nosotti, L., Palazzo, Donatella, Pellicelli, A., Romano, M., Sarrecchia, C., Sforza, D., Sorbo, M. C., Spaziante, M., Svicher, V., Tisone, G., Vespasiani Gentilucci, U., D'Adamo, G., Mangia, A., Maida, I., Mura, M. S., Falconi, L., Di Giammartino, D., Di Maio, V., Cento, V., Lenci, I., Aragri, M., Rossi, P., Barbaliscia, S., Melis, M., Verucchi, G., Magni, C., Teti, E., Bertoli, A., Antonucci, F., Bellocchi, M., Micheli, V., Masetti, C., Landonio, S., Francioso, S., Santopaolo, F., Pellicelli, A., Calvaruso, V., Gianserra, L., Siciliano, M., Romagnoli, D., Cozzolongo, R., Grieco, A., Vecchiet, J., Morisco, F., Merli, M., Brancaccio, G., Di Biagio, A., Loggi, E., Mastroianni, C., Pace Palitti, V., Tarquini, P., Puoti, M., Taliani, G., Sarmati, L., Picciotto, A., Vullo, V., Caporaso, N., Paoloni, M., Pasquazzi, C., Rizzardini, G., Parruti, G., Craxã¬, A., Babudieri, S., Andreoni, M., Angelico, M., Perno, C., Ceccherini-Silberstein, F., Mariani, R., Iapadre, N., Grimaldi, A., Andreone, P., Menzaghi, B., Quirino, T., Pisani, V., Torti, C., Bruzzone, B., De Maria, A., Marenco, S., Nicolini, L., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, M., Aghemo, A., Boccaccio, V., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Lleo, A., Mancon, A., Monico, S., Niero, F., Russo, M., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Gaeta, G., Lembo, V., Sangiovanni, V., DI MARCO, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pieri, A., Polilli, E., Sozio, F., Antenucci, F., Baiocchi, L., Biliotti, E., Biolato, M., Carioti, L., Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettorre, G., De Leonardis, F., De Sanctis, A., Di Paolo, D., Furlan, C., Gallo, P., Gasbarrini, A., Giannelli, V., Grieco, S., Lambiase, L., Lattanzi, B., Lula, R., Malagnino, V., Manuelli, M., Miglioresi, L., Milana, M., Moretti, A., Nosotti, L., Palazzo, D., Romano, M., Sarrecchia, C., Sforza, D., Sorbo, M., Spaziante, M., Svicher, V., Tisone, G., Vespasiani-Gentilucci, U., D'Adamo, G., Mangia, A., Maida, I., Mura, M., Falconi, L., Di Giammartino, D., Di Maio, V, Cento, V, Lenci, I, Aragri, M, Rossi, P, Barbaliscia, S, Melis, M, Verucchi, G, Magni, C, Teti, E, Bertoli, A, Antonucci, F, Bellocchi, M, Micheli, V, Masetti, C, Landonio, S, Francioso, S, Santopaolo, F, Pellicelli, A, Calvaruso, V, Gianserra, L, Siciliano, M, Romagnoli, D, Cozzolongo, R, Grieco, A, Morisco, F, Merli, M, Brancaccio, G, Di Biagio, A, Loggi, E, Mastroianni, C, Pace Palitti, V, Tarquini, P, Puoti, M, Taliani, G, Sarmati, L, Picciotto, A, Vullo, V, Caporaso, N, Paoloni, M, Pasquazzi, C, Rizzardini, G, Parruti, G, Craxì, A, Babudieri, S, Andreoni, M, Angelico, M, Perno, C, Ceccherini-Silberstein, F, Velia C. Di Maio, Valeria Cento, Ilaria Lenci, Marianna Aragri, Piera Rossi, Silvia Barbaliscia, Michela Meli, Gabriella Verucchi, Carlo F. Magni, Elisabetta Teti, Ada Bertoli, Francesco Paolo Antonucci, Maria C. Bellocchi, Valeria Micheli, Chiara Masetti, Simona Landonio, Simona Francioso, Francesco Santopaolo, Adriano M. Pellicelli, Vincenza Calvaruso, Laura Gianserra, Massimo Siciliano, Dante Romagnoli, Raffaele Cozzolongo, Antonio Grieco, Jacopo Vecchiet, Filomena Morisco, Manuela Merli, Giuseppina Brancaccio, Antonio Di Biagio, Elisabetta Loggi, Claudio M. Mastroianni, Valeria Pace Palitti, Pierluigi Tarquini, Massimo Puoti, Gloria Taliani, Loredana Sarmati, Antonino Picciotto, Vincenzo Vullo, Nicola Caporaso, Maurizio Paoloni, Caterina Pasquazzi, Giuliano Rizzardini, Giustino Parruti, Antonio Craxì, Sergio Babudieri, Massimo Andreoni, Mario Angelico, Carlo F. Perno, Francesca Ceccherini-Silberstein, for the HCV Italian Resistance Network Study Group: [.., P. Andreone, E. Loggi, G. Verucchi, ], Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M., Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxã¬, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F., Ceccherini-Silberstein, Francesca, Nicolini, L. A., Magni, C. F., Russo, M. L., Gaeta, G. B., Di Marco, V., Di Maio, V. C., Sorbo, M. C., Mura, M. S., Di Maio, Velia C, Magni, Carlo F, Bellocchi, Maria C, Pellicelli, Adriano M, Mastroianni, Claudio M, Craxì, Antonio, Perno, Carlo F, and Ceccherini Silberstein, Francesca
- Subjects
Male ,0301 basic medicine ,hepatitis C virus ,Sustained Virologic Response ,Sofosbuvir ,Hepacivirus ,Drug Resistance ,resistance-associated substitutions ,Viral Nonstructural Proteins ,VARIANTS ,NS5A ,medicine.disease_cause ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Recurrence ,INFECTION ,antiviral therapy ,Medicine ,hepatitis C viru ,Viral ,Treatment Failure ,Chronic ,direct-acting antivirals ,resistance test ,hepatology ,biology ,GENOTYPE 1 ,virus diseases ,Middle Aged ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Hepatitis C ,Italy ,Combination ,Interferon ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Author Keywords:antiviral therapy ,RIBAVIRIN ,Sequence Analysis ,Human ,medicine.drug ,medicine.medical_specialty ,Daclatasvir ,Genotype ,Hepatitis C virus ,Antiviral Agents ,LONG-TERM PERSISTENCE ,DACLATASVIR ,03 medical and health sciences ,Drug Therapy ,Aged ,Drug Resistance, Viral ,Hepatitis C, Chronic ,Humans ,Interferons ,Mutation ,Ribavirin ,Sequence Analysis, DNA ,Hepatology ,TREATMENT-NAIVE ,Internal medicine ,Antiviral Agent ,resistance-associated substitution ,direct-acting antiviral ,Hepaciviru ,resistance test KeyWords Plus:HEPATITIS-C VIRUS ,business.industry ,Viral Nonstructural Protein ,DNA ,biology.organism_classification ,Clinical trial ,030104 developmental biology ,SOFOSBUVIR ,chemistry ,Sequence Analysi ,Immunology ,business - Abstract
Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and whenever possible at baseline (N= 70). Results: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P= 2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. Conclusions: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring.
- Published
- 2017
9. SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection
- Author
-
Patrick T F Kennedy, Ada Bertoli, Carlo Federico Perno, Massimo Marignani, Jens Verheyen, Paoloni Maurizio, L. Carioti, T. Mari, Vincenzo Malagnino, Carlotta Cerva, L. Colagrossi, Angelico Mario, Giustino Parruti, Jacopo Vecchiet, A. Battisti, Francesca Ceccherini Silberstein, A. Iuvara, Olympia E. Anastasiou, Upkar S. Gill, Claudio Maria Mastroianni, Miriam Lichtner, L. Piermatteo, Giuseppe Maria De Sanctis, Caterina Pasquazzi, Romina Salpini, Sandro Grelli, Massimo Andreoni, N. Iapadre, Loredana Sarmati, Marianna Aragri, and Valentina Svicher
- Subjects
HBsAg ,Hepatology ,Hbeag negative ,In vivo ,C-terminus ,Hbv genotype ,Secretion ,Biology ,Affect (psychology) ,Virology ,In vitro - Published
- 2019
10. SAT-211-HEV infection in Italy: Beyond the hepatic disease
- Author
-
Picchi, Giovanna, primary, Ricciardi, Alessandra, additional, Marola, Lara, additional, Madonna, Elisabetta, additional, Chionne, Paola, additional, Villano, Umbertina, additional, Marcantonio, Cinzia, additional, Bruni, Roberto, additional, Equestre, Michele, additional, Pisani, Giulio, additional, Iapadre, Nerio, additional, Mariani, Maurizio, additional, Cellini, Antonio, additional, Orneto, Lucia, additional, Barnabei, Remo, additional, Santini, Simonetta, additional, D’Alessandro, Margherita, additional, Cacciatore, Pierluigi, additional, Sozio, Federica, additional, Necozione, Stefano, additional, Parruti, Giustino, additional, Paoloni, Maurizio, additional, Ciccaglione, Annarita, additional, and Grimaldi, Alessandro, additional
- Published
- 2019
- Full Text
- View/download PDF
11. Comparative evaluation of subtyping tools for surveillance of newly emerging HIV-1 strains
- Author
-
Fabeni, Lavinia, Berno, Giulia, Fokam, Joseph, Bertoli, Ada, Alteri, Claudia, Gori, Caterina, Forbici, Federica, Takou, Desirã, Vergori, Alessandra, Zaccarelli, Mauro, Maffongelli, Gaetano, Borghi, Vanni, Latini, Alessandra, Pennica, Alfredo, Mastroianni, Claudio Maria, Montella, Francesco, Mussini, Cristina, Andreoni, Massimo, Antinori, Andrea, Perno, Carlo Federico, Santoro, Maria Mercedes, Armenia, Daniele, Bellocchi, Maria Concetta, Biddittu, Andrea, Bruni, Massimiliano, Buonomini, Anna Rita, Carioti, Luca, Ceccherini Silberstein, Francesca, Cerva, Carlotta, Cesta, Novella, Di Carlo, Domenico, Dori, Luca, Foroghi, Luca, Gentilotti, Elisa, Giannella, Sara, Guenci, Tania, Malagnino, Vincenzo, Ricciardi, Alessandra, Romani, Marzia, Salpini, Omina, Sarmati, Loredana, Scutari, Rossana, Serafini, Valentina, Sordillo, Pasquale, Stazi, Francesca, Stingone, Cristof, Svicher, Valentina, Teti, Elisabetta, Viscione, Magdalena, Abbate, Isabella, Acinapura, Rosa, Alba, Lucia, Ammassari, Adriana, Baldini, Franco, Bellagamba, Rita, Boumis, Evangelo, Capobianchi, Maria Rosaria, Carta, Stefania, Cicalini, Stefania, Continenza, Fabio, De Carli, Gabriella, D'Arrigo, Roberta, D'Offizi, Gianpiero, Fedele, Valentina, Galati, Vincenzo, Giannetti, Alberto, Girardi, Enrico, Grisetti, Susanna, Libertone, Raffaella, Liuzzi, Giuseppina, Lorenzini, Patrizia, Maddaluno, Rita, Mariano, Andrea, Navarra, Assunta, Nicastri, Emanuele, Nurra, Giuseppina, Orchi, Nicoletta, Palummieri, Antonio, Pinnetti, Carmela, Pittalis, Silvia, Pizzi, Daniele, Puro, Vincenzo, Sampaolesi, Alessandro, Sciarrone, Maria Rosaria, Scognamiglio, Paola, Sias, Catia, Visco Comandini, Ubaldo, Colafigli, Manuela, Cristaudo, Antonio, Giuliani, Massimo, Pacifici, Anna, Di Sora, Fiorella, Iebba, Filippo, Lichtner, Miriam, Marocco, Raffaella, Bernardi, Stefania, Anzalone, Enza, Bonaventura, Maria Elena, Marchili, Mauro, Pitorri, Antonella, Di Francesco, Luigi Falconi, Di Giammartino, Dante, Caterini, Antonio, Armignacco, Orlando, Mariani, Rinalda, Paoloni, Maurizio, Parruti, Giustino, Pieri, Alessandro, Sozio, Federica, Cellini, Antonio, Grimaldi, Alessandro, Mariani, Maurizio, Picchi, Giovanna, Gennari, William, Nanfack, Aubin J., Ndjolo, Alexis, and Torimiro, Judith N.
- Subjects
0301 basic medicine ,Microbiology (medical) ,Settore MED/17 - Malattie Infettive ,Human immunodeficiency virus (HIV) ,Context (language use) ,HIV Infections ,Biology ,medicine.disease_cause ,Sensitivity and Specificity ,Genetic diversity ,Comparative evaluation ,03 medical and health sciences ,HIV Protease ,Virology ,Genotype ,Circulating recombinant forms ,HIV-1 ,Phylogeny ,Subtypes ,Subtyping automated tools ,Databases, Genetic ,medicine ,Humans ,CRFS ,Automation, Laboratory ,Base Sequence ,Sequence Analysis, RNA ,circulating recombinant forms ,genetic diversity ,phylogeny ,subtypes ,subtyping automated tools ,microbiology ,Gold standard (test) ,Subtyping ,HIV Reverse Transcriptase ,Molecular Typing ,030104 developmental biology ,Epidemiological surveillance - Abstract
HIV-1 non-B subtypes/circulating recombinant forms (CRFs) are increasing worldwide. Since subtype identification can be clinically relevant, we assessed the added value in HIV-1 subtyping using updated molecular phylogeny (Mphy) and the performance of routinely used automated tools. Updated Mphy (2015 updated reference sequences), used as a gold standard, was performed to subtype 13,116 HIV-1 protease/reverse transcriptase sequences and then compared with previous Mphy (reference sequences until 2014) and with COMET, REGA, SCUEAL, and Stanford subtyping tools. Updated Mphy classified subtype B as the most prevalent (73.4%), followed by CRF02_AG (7.9%), C (4.6%), F1 (3.4%), A1 (2.2%), G (1.6%), CRF12_BF (1.2%), and other subtypes (5.7%). A 2.3% proportion of sequences were reassigned as different subtypes or CRFs because of misclassification by previous Mphy. Overall, the tool most concordant with updated Mphy was Stanford-v8.1 (95.4%), followed by COMET (93.8%), REGA-v3 (92.5%), Stanford-old (91.1%), and SCUEAL (85.9%). All the tools had a high sensitivity (≥98.0%) and specificity (≥95.7%) for subtype B. Regarding non-B subtypes, Stanford-v8.1 was the best tool for C, D, and F subtypes and for CRFs 01, 02, 06, 11, and 36 (sensitivity, ≥92.6%; specificity, ≥99.1%). A1 and G subtypes were better classified by COMET (92.3%) and REGA-v3 (98.6%), respectively. Our findings confirm Mphy as the gold standard for accurate HIV-1 subtyping, although Stanford-v8.1, occasionally combined with COMET or REGA-v3, represents an effective subtyping approach in clinical settings. Periodic updating of HIV-1 reference sequences is fundamental to improving subtype characterization in the context of an effective epidemiological surveillance of non-B strains.
- Published
- 2017
12. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
- Author
-
Di Maio, Velia Chiara, primary, Cento, Valeria, additional, Aragri, Marianna, additional, Paolucci, Stefania, additional, Pollicino, Teresa, additional, Coppola, Nicola, additional, Bruzzone, Bianca, additional, Ghisetti, Valeria, additional, Zazzi, Maurizio, additional, Brunetto, Maurizia, additional, Bertoli, Ada, additional, Barbaliscia, Silvia, additional, Galli, Silvia, additional, Gennari, William, additional, Baldanti, Fausto, additional, Raimondo, Giovanni, additional, Perno, Carlo Federico, additional, Ceccherini-Silberstein, Francesca, additional, Andreone, Pietro, additional, Andreoni, Massimo, additional, Angelico, Mario, additional, Babudieri, Sergio, additional, Barbarini, Giorgio, additional, Boccaccio, Vincenzo, additional, Boglione, Lucio, additional, Bolis, Matteo, additional, Bonora, Stefano, additional, Borghi, Vanni, additional, Brancaccio, Giuseppina, additional, Bruno, Savino, additional, Cacciatore, Pierluigi, additional, Calvaruso, Vincenza, additional, Caporaso, Nicola, additional, Ciaccio, Antonio, additional, Ciancio, Alessia, additional, Colombatto, Piero, additional, Cozzolongo, Raffaele, additional, Craxì, Antonio, additional, D'Ambrosio, Cecilia, additional, D'Ettorre, Gabriella, additional, De Luca, Andrea, additional, Di Biagio, Antonio, additional, Di Perri, Giovanni, additional, Francioso, Simona, additional, Gaeta, Giovanni Battista, additional, Giorgini, Alessia, additional, Grieco, Antonio, additional, Gubertini, Guido, additional, Gulminetti, Roberto, additional, Lambiase, Lara, additional, Lenci, Ilaria, additional, Lichtner, Miriam, additional, Maida, Ivana, additional, Marenco, Simona, additional, Marinaro, Letizia, additional, Maserati, Renato, additional, Masetti, Chiara, additional, Melis, Michela, additional, Meregalli, Elisa, additional, Micheli, Valeria, additional, Morisco, Filomena, additional, Niero, Fosca, additional, Nicolini, Laura Ambra, additional, Palitti, Valeria Pace, additional, Paoloni, Maurizio, additional, Parruti, Giustino, additional, Pasquazzi, Caterina, additional, Pellicelli, Adriano, additional, Polilli, Ennio, additional, Ponti, Maria Laura, additional, Puoti, Massimo, additional, Rendina, Maria, additional, Rizzardini, Giuliano, additional, Rossetti, Barbara, additional, Ruggiero, Tina, additional, Sangiovanni, Vincenzo, additional, Starace, Mario, additional, Sticchi, Laura, additional, Tarquini, Pierluigi, additional, Toniutto, Pierluigi, additional, and Vullo, Vincenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
13. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
- Author
-
Di Maio, Velia C, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F, Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C, Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M, Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F, Ceccherini-Silberstein, Francesca, Grieco, Antonio (ORCID:0000-0002-0544-8993), Di Maio, Velia C, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F, Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C, Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M, Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F, Ceccherini-Silberstein, Francesca, and Grieco, Antonio (ORCID:0000-0002-0544-8993)
- Abstract
BACKGROUND & AIMS: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. METHODS: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70). RESULTS: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. CONCLUSIONS: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resis
- Published
- 2017
14. Web-Based HIV Testing in Abruzzo, Italy: Analysis of 15-Month Activity Results
- Author
-
Polilli, Ennio, primary, Sozio, Federica, additional, Di Stefano, Paola, additional, Sciacca, Antonina, additional, Ursini, Tamara, additional, Paoloni, Maurizio, additional, Vecchiet, Jacopo, additional, Di Giammartino, Dante, additional, Sciotti, Maria Pina, additional, Grimaldi, Alessandro, additional, Cortesi, Valerio, additional, Fazii, Paolo, additional, Ricci, Elena, additional, D'Amario, Claudio, additional, Ippolito, Giuseppe, additional, Pippa, Lucio, additional, and Parruti, Giustino, additional
- Published
- 2016
- Full Text
- View/download PDF
15. High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening
- Author
-
Polilli, Ennio, primary, Tontodonati, Monica, additional, Flacco, Maria Elena, additional, Ursini, Tamara, additional, Striani, Palmira, additional, Di Giammartino, Dante, additional, Paoloni, Maurizio, additional, Vallarola, Luigi, additional, Pressanti, Gabriella Lucidi, additional, Fragassi, Giorgia, additional, Accorsi, Patrizia, additional, Manzoli, Lamberto, additional, and Parruti, Giustino, additional
- Published
- 2015
- Full Text
- View/download PDF
16. Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
- Author
-
Di Maio, Velia Chiara, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Barbaliscia, Silvia, Francioso, Simona, Stefania Paolucci, Melis, Michela, Verucchi, Gabriella, Coppola, Nicola, Magni, Carlo F., Santopaolo, Francesco, Landonio, Simona, Ghisetti, Valeria, Starace, Mario, D Ambrosio, Cecilia, Calvaruso, Vincenzo, Caporasol, Nicola, Pasquazzi, Caterina, Maida, Ivana, Picciotto, Antonino, Di Biagio, Antonio, Sticchi, Laura, Cozzolongo, Raffaele, Romagnoli, Dante, Biolato, Marco, Vecchiet, Jacopo, D Ettorre, Gabriella, Merli, Manuela, Gaeta, Giovanni B., Ciancio, Alessia, Marinaro, Letizia, Andreone, Pietro, Barbarini, Giorgio, Gulminetti, Roberto, Palitti, Valeria Pace, Tarquini, Perluigi, Puoti, Massimo, Sangiovanni, Vincenzo, Paoloni, Maurizio, Babudieri, Sergio, Rizzardini, Giuliano, Bruno, Savino, Andreoni, Massimo, Pellicelli, Adriano M., Parruti, Giustino, Craxi, Antonio, Angelico, Mario, Perno, Carlo F., and Ceccherini-Silberstein, Francesca
17. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
- Author
-
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, and Ceccherini-Silberstein F
- Subjects
- Aged, Drug Therapy, Combination, Female, Genotype, Hepacivirus drug effects, Humans, Interferons therapeutic use, Italy, Male, Middle Aged, Mutation, Recurrence, Ribavirin therapeutic use, Sequence Analysis, DNA, Sofosbuvir therapeutic use, Sustained Virologic Response, Treatment Failure, Antiviral Agents therapeutic use, Drug Resistance, Viral genetics, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Viral Nonstructural Proteins genetics
- Abstract
Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures., Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70)., Results: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure., Conclusions: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
18. Effective control of psoriasis by etanercept in a patient with HCV-related diseases.
- Author
-
Piccolo D, Di Cesare A, Fargnoli MC, Paoloni M, Vecchiotti S, and Peris K
- Subjects
- Etanercept, Humans, Male, Middle Aged, Psoriasis complications, Dermatologic Agents therapeutic use, Hepatitis C complications, Immunoglobulin G therapeutic use, Psoriasis drug therapy, Receptors, Tumor Necrosis Factor therapeutic use
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.